The introduction of nicotinamide to be a nicotine replacement in e-cigarette and smokeless merchandise represents a major regulatory challenge to the FDA. Nicotinamide does not have nicotinic receptor agonist activity and is known to act as a sedative at substantial dosages6. The promises produced by Nicotine River, ECBlend, and other suppliers tha